The mission of the North Central Cancer Treatment Group (NCCTG) is to improve the duration and quality of life of cancer patients by performing high-quality clinical and translational research in the community setting. The NCCTG (Biospecimen Resource will support the NCCTG mission by providing superior biospecimens from patients enrolled on NCCTG trials that 1) are fully and consistently annotated, 2) have been collected under optimized standard conditions, 3) have undergone quality assessment, and 4) are stored under controlled conditions allowing efficient retrieval for distribution to qualified researchers. The five specific aims of this application are 1) To maximize collection of biospecimens from patients enrolled on NCCTG and other cooperative group clinical trials.
This aim will serve to increase the numbers of biospecimens available for translational research so that more studies with sufficient statistical power can be accommodated;2) To consistently and completely annotate biospecimens collected.
This aim will serve to provide a crucial element in translational research, namely to define the context of standard clinical-pathologic indices, treatments, response to treatment, and disease outcome within which the significance of the measured biologic parameters of translational studies will be evaluated;3) To develop standard operating procedures (SOP) for collecting, processing, and storing biospecimens. The use of SOPs will enhance the Biospecimen Resource by providing uniformity so that biospecimens for a given translational study are comparable with one another;4) To develop new methods for analysis of biospecimens. Technologies are constantly developing that expand our ability to analyze biospecimens. In this aim we describe three technologies that we are refining (tissue microarray construction) and developing (analysis of circulating tumor cells and extraction of RNA from formalin-fixed paraffin embedded tissue blocks) as examples of new methodologies that expand the use of biospecimens;and 5) To provide oversight to the resource and a mechanism for access to the resource for the research community.
This aim will describe the oversight of the Biospecimen Resource and how we will provide a public link to the mechanism for requesting biospecimens. A prioritization system and evaluation criteria are defined.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J1))
Program Officer
Lubensky, Irina
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Sinicrope, Frank A; Shi, Qian; Allegra, Carmen J et al. (2017) Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Oncol 3:472-480
Reinholz, Monica M; Chen, Beiyun; Dueck, Amylou C et al. (2017) IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831. Clin Cancer Res 23:4203-4211
Lee, Adam M; Shi, Qian; Alberts, Steven R et al. (2016) Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet Genomics 26:133-7
Perez, Edith A; Thompson, E Aubrey; Ballman, Karla V et al. (2015) Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. J Clin Oncol 33:701-8
Yoon, Harry H; Shi, Qian; Alberts, Steven R et al. (2015) Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients. J Natl Cancer Inst 107:
Sinicrope, Frank A; Shi, Qian; Smyrk, Thomas C et al. (2015) Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology 148:88-99
Perez-Carbonell, L; Sinicrope, F A; Alberts, S R et al. (2015) MiR-320e is a novel prognostic biomarker in colorectal cancer. Br J Cancer 113:83-90
Zhu, Shijun; Kisiel, Walter; Lu, Yang J et al. (2015) Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody. J Drug Target 23:257-65
Sinicrope, Frank A; Mahoney, Michelle R; Yoon, Harry H et al. (2015) Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). Clin Cancer Res 21:5294-304
Huang, Jocelin; Nair, Suresh G; Mahoney, Michelle R et al. (2014) Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer 13:100-9

Showing the most recent 10 out of 48 publications